Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort-Reference-Cited by-同舟云学术

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

Published:2021-12 Issue:12 Volume:16 Page:2040-2050
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Dziadziuszko Rafal,Mok Tony,Peters Solange,Han Ji-Youn,Alatorre-Alexander Jorge,Leighl Natasha,Sriuranpong Virote,Pérol Maurice,de Castro Junior Gilberto,Nadal Ernest,de Marinis Filippo,Frontera Osvaldo Arén,Tan Daniel S.W.,Lee Dae Ho,Kim Hye Ryun,Yan Mark,Riehl Todd,Schleifman Erica,Paul Sarah M.,Mocci Simonetta,Patel Rajesh,Assaf Zoe June,Shames David S.,Mathisen Michael S.,Gadgeel Shirish M.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Updated September 2020;Planchard;Ann Oncol,2018

3. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer;Lim;Ann Oncol,2015

4. Liquid biopsy as surrogate to tissue in lung cancer for molecular profiling: a meta-analysis;Mlika;Curr Respir Med Rev,2018

5. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer;Aggarwal;JAMA Oncol,2019

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing the potential of genomic characterization of mutational profiles to improve early diagnosis of lung cancer;Expert Review of Molecular Diagnostics;2024-09-12

2. Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center;Cancers;2024-07-10

3. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial;Nature Medicine;2024-06-19

4. NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers;The Journal of Liquid Biopsy;2024-06

5. Recent nanotechnological aspects and molecular targeting strategies for lung cancer therapy;Journal of Nanoparticle Research;2024-05